Eledon Pharmaceuticals (ELDN) Other Non-Current Liabilities (2015 - 2026)

Eledon Pharmaceuticals has reported Other Non-Current Liabilities for 6 years, with the latest figure at $30.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 12.72% year-over-year to $30.4 million; the trailing twelve-month figure through Mar 2026 stood at $30.4 million (down 12.72% YoY), and the FY2025 full-year result was $11.4 million, down 74.55% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $30.4 million, up from $11.4 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $120.8 million in Q2 2024, with the low at $11.4 million in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $49.0 million across 4 years, with a median of $39.8 million in 2024.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 115.06% — and 2025, when it tumbled 81.37%.
• Eledon Pharmaceuticals' Other Non-Current Liabilities stood at $76.2 million in 2023, then sank by 41.13% to $44.9 million in 2024, then sank by 74.55% to $11.4 million in 2025, then surged by 166.1% to $30.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $30.4 million (Q1 2026), $11.4 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.